Kurome Therapeutics
Daniel Heller as General Partner and Chief Investment Officer at Affinity Asset Advisors, former Director of Research at Perceptive Advisors and founding Board Member at Silagene Inc.
This person is not in the org chart
This person is not in any offices
Kurome Therapeutics
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.